Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They ...

Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges. Trading volume skyrocketed to 665 times its ...

Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor ...

Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing ...

(PRNewsfoto/Hoth Therapeutics Inc.) "These compelling findings reinforce GDNF's potential to fundamentally alter the way we approach obesity treatment," said Robb Knie CEO of Hoth Therapeutics.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are ...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic ...